AstraZeneca earnings q3 2018


“Every single new product we’ve launched is doing very well,” he added. Shares of the company were up 1.8 percent on Thursday morning.

Total revenue, however, fell 14 percent in dollar terms to $5.34 billion and core earnings per share, which exclude some items, were down 37 percent to 71 cents, reflecting lower income from divestments and investment behind new drug launches.

Analysts, on average, had forecast earnings of 72 cents on revenue of $5.30 billion, Refinitiv data showed. For the full year, the company kept its financial guidance unchanged.

Source link

Products You May Like

Articles You May Like

Analysts downgraded these stocks due to the US-China trade war
Arena Pharmaceuticals, Yext, IAC, and more
Wall Street analysts stick with Pinterest despite rough first earnings report
China’s currency is a strong barometer on US-China trade
China powering ahead of the US in race for mega start-ups, unicorns

Leave a Reply

Your email address will not be published. Required fields are marked *